On the other hand, another group reported that PDK1 activity was increased in AD brain, and that PDK1 inhibitor enhanced α-secretase activity and reduced amyloid plaques in APP transgenic (Tg) mouse models of AD (Pietri et al., 2013), suggesting a gain-of-function mechanism. Here, APP is linked to Alzheimer disease.